Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

1.4 Associated with connective tissue disease, HIV infection, portal hypertension, congenital heart disease, schistosomiasis ALK-1 indicates activin receptor-like kinase 1; BMPR2, bone morphogenetic ...

This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading ... Researchers Identify Over 2,000 Genetic Signals Linked to Blood ...

The aim of this paper is to review the existing reports of intravitreal anti-VEGF-induced ocular hypertension, and to provide evidence from the existing literature regarding the plausibility of NO ...

Pulmonary hypertension (PH) increases the mortality of preterm infants with bronchopulmonary dysplasia (BPD). There are no curative therapies for this disease. Lung endothelial carnitine ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...

Intravitreal injections of anti-VEGF agents have become an important tool in the management of some of the most common retinal and choroidal neovascular diseases. Adverse effects are uncommon ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begin in 2028.